I-Ming Wang
Director, Translational Oncology Lead Pfizer
Seminars
Wednesday 22nd July 2026
Beyond Detection: Using ctDNA to Refine Patient Selection, Predict Durability & Inform Resistance in Targeted Therapy
2:15 pm
- Leveraging ctDNA across Phase I and Phase III trials to correlate molecular response with long-term efficacy, including differentiating early progressors from patients achieving multi-year durable benefit
- Using ctDNA to interrogate why certain targeted therapies deliver exceptional outcomes, while identifying resistance mechanisms that inform rational combination strategies
- Challenging current enrollment paradigms by examining variant allele frequency thresholds and co-mutation burden, and exploring how ctDNA insights should reshape regulatory and clinical trial design frameworks
